Novartis: signs new agreement with BioNTech
(CercleFinance.com) - Novartis has signed a new initial agreement with BioNTech to support the filling and finishing of the Pfizer-BioNTech COVID-19 mRNA vaccine.
Novartis will use its sterile manufacturing facilities at its Novartis Technical Operations site in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
This new agreement follows an earlier supply agreement to fill and finish over 50 million doses in 2021 at the Novartis Stein site in Switzerland
The share is currently up about 0.3%, about double the pretty index in Zurich.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Novartis will use its sterile manufacturing facilities at its Novartis Technical Operations site in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
This new agreement follows an earlier supply agreement to fill and finish over 50 million doses in 2021 at the Novartis Stein site in Switzerland
The share is currently up about 0.3%, about double the pretty index in Zurich.
Copyright (c) 2021 CercleFinance.com. All rights reserved.